M

Marinomed Biotech AG
VSE:MARI

Watchlist Manager
Marinomed Biotech AG
VSE:MARI
Watchlist
Price: 41.8 EUR 1.7% Market Closed
Market Cap: 20.6m EUR

Wall Street
Price Targets

MARI Price Targets Summary
Marinomed Biotech AG

Wall Street analysts forecast MARI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MARI is 42.84 EUR with a low forecast of 42.42 EUR and a high forecast of 44.1 EUR.

Lowest
Price Target
42.42 EUR
1% Upside
Average
Price Target
42.84 EUR
2% Upside
Highest
Price Target
44.1 EUR
6% Upside
Marinomed Biotech AG Competitors:
Price Targets
RX
Biosyent Inc
12% Upside
GUD
Knight Therapeutics Inc
34% Upside
600993
Mayinglong Pharmaceutical Group Co Ltd
35% Upside
JUBLPHARMA
Jubilant Pharmova Ltd
16% Upside
4536
Santen Pharmaceutical Co Ltd
27% Upside
AJANTPHARM
Ajanta Pharma Ltd
21% Upside

Revenue
Forecast

Revenue Estimate
Marinomed Biotech AG

For the last 6 years the compound annual growth rate for Marinomed Biotech AG's revenue is 11%. The projected CAGR for the next 3 years is -24%.

11%
Past Growth
-24%
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Marinomed Biotech AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

Net Income
Forecast

Net Income Estimate
Marinomed Biotech AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MARI's stock price target?
Price Target
42.84 EUR

According to Wall Street analysts, the average 1-year price target for MARI is 42.84 EUR with a low forecast of 42.42 EUR and a high forecast of 44.1 EUR.

What is Marinomed Biotech AG's Revenue forecast?
Projected CAGR
-24%

For the last 6 years the compound annual growth rate for Marinomed Biotech AG's revenue is 11%. The projected CAGR for the next 3 years is -24%.

Back to Top